Observational studyBreast cancer research and treatment2026

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Manuel Hörner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.